BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23800140)

  • 1. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers.
    Xun YH; Zang GQ; Guo JC; Yu XL; Liu H; Xiang J; Liu J; Shi JP
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1746-55. PubMed ID: 23800140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment.
    Chen EQ; Wang TT; Bai L; Tao CM; Liang T; Liu C; Liao J; Tang H
    Antivir Ther; 2013; 18(8):955-65. PubMed ID: 23639885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients.
    Ahmed FA; Bajaifar MS; Ahmed MA; Alalwan A; Sanai FA; Albeladi K; Aljumah AA; Sanai FM
    Saudi J Gastroenterol; 2019; 25(5):286-292. PubMed ID: 31044750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
    Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
    Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.
    Brunetto MR; Oliveri F; Colombatto P; Moriconi F; Ciccorossi P; Coco B; Romagnoli V; Cherubini B; Moscato G; Maina AM; Cavallone D; Bonino F
    Gastroenterology; 2010 Aug; 139(2):483-90. PubMed ID: 20451520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B].
    Tu XL; Xiao YQ; Chen F
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):28-32. PubMed ID: 19203448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
    Lee JM; Ahn SH; Kim HS; Park H; Chang HY; Kim DY; Hwang SG; Rim KS; Chon CY; Han KH; Park JY
    Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients.
    Martinot-Peignoux M; Carvalho-Filho R; Lapalus M; Netto-Cardoso AC; Lada O; Batrla R; Krause F; Asselah T; Marcellin P
    J Hepatol; 2013 Jun; 58(6):1089-95. PubMed ID: 23369792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers.
    Park H; Lee JM; Seo JH; Kim HS; Ahn SH; Kim DY; Han KH; Chon CY; Park JY
    Liver Int; 2012 May; 32(5):796-802. PubMed ID: 22128792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China.
    Li Q; Li W; Huang Y; Chen L
    J Viral Hepat; 2016 Nov; 23(11):912-919. PubMed ID: 27375134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver function and hepatitis markers in carriers of hepatitis B virus in New Zealand.
    Hopkirk N; Moyes CD; Lucas CR
    N Z Med J; 2000 Apr; 113(1107):114-6. PubMed ID: 10834277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
    Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
    J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres.
    Congly SE; Wong P; Al-Busafi SA; Doucette K; Fung SK; Ghali P; Fonseca K; Myers RP; Osiowy C; Coffin CS
    Liver Int; 2013 Oct; 33(9):1363-9. PubMed ID: 23763288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are serum quantitative hepatitis b surface antigen levels, liver histopathology and viral loads related in chronic hepatitis b-infected patients?
    Balkan A; Namiduru M; Balkan Y; Mete AO; Karaoglan I; Bosnak VK
    Saudi J Gastroenterol; 2016; 22(3):208-14. PubMed ID: 27184639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease.
    Mohamadnejad M; Montazeri G; Fazlollahi A; Zamani F; Nasiri J; Nobakht H; Forouzanfar MH; Abedian S; Tavangar SM; Mohamadkhani A; Ghoujeghi F; Estakhri A; Nouri N; Farzadi Z; Najjari A; Malekzadeh R
    Am J Gastroenterol; 2006 Nov; 101(11):2537-45. PubMed ID: 17029616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of quantitative hepatitis B virus surface antigen testing in pregnancy in predicting vertical transmission risk.
    Samadi Kochaksaraei G; Congly SE; Matwiy T; Castillo E; Martin SR; Charlton CL; Coffin CS
    Liver Int; 2016 Nov; 36(11):1604-1610. PubMed ID: 27059287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection.
    Papatheodoridis GV; Hadziyannis E; Tsochatzis E; Chrysanthos N; Georgiou A; Kafiri G; Manolakopoulos S; Tiniakos DG; Giannousis I; Manesis EK; Archimandritis AJ
    Gut; 2008 Apr; 57(4):500-6. PubMed ID: 18025069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation.
    Maimone S; Caccamo G; Squadrito G; Alibrandi A; Saffioti F; Spinella R; Raffa G; Pollicino T; Raimondo G
    Liver Int; 2017 Mar; 37(3):362-368. PubMed ID: 27606573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.